{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:18:39Z","timestamp":1777393119876,"version":"3.51.4"},"reference-count":115,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>Alzheimer\u2019s disease is a devastating neurodegenerative condition that exerts a significant global burden. Despite recent efforts, disease modifying therapies remain extremely limited, with a tremendous proportion of patients having to rely on symptomatic treatment only. Epidemiological and pathological overlaps exist between Alzheimer\u2019s disease and diabetes mellitus type 2, with people with diabetes mellitus type 2 at a significantly increased risk of developing Alzheimer\u2019s disease in the future. Incretin mimetics, also known as GLP-1\/GIP receptor agonists, are useful tools licensed for the treatment of diabetes mellitus type 2 which have recently been the subject of news coverage for their off-label use as weight loss medications. Emerging evidence highlights the possible neuroprotective function of incretin mimetics in models of Alzheimer\u2019s disease as well as in clinical studies. This review details the pre-clinical and clinical studies that have explored the effectiveness of incretin mimetics to alleviate Alzheimer\u2019s disease associated pathology and cognitive impairment, while also highlighting the progress made to examine the effectiveness of these molecules in Parkinson\u2019s disease. Should clinical trials prove effective, incretin mimetics may be able to be repurposed and become useful novel tools as disease-modifying treatments for Alzheimer\u2019s disease and other neurodegenerative diseases.<\/jats:p>","DOI":"10.3233\/jad-240730","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:54:36Z","timestamp":1729248876000},"page":"S357-S370","source":"Crossref","is-referenced-by-count":5,"title":["Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"101","author":[{"given":"Harry","family":"Crook","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Edison","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London, UK"},{"name":"Cardiff University, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240730_ref1","first-page":"97","article-title":"Burden of illness in people with Alzheimer\u2019s disease: A systematic review of epidemiology, comorbidities and mortality","volume":"11","author":"Lanctot","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-240730_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2023.09.008","article-title":"Economic burden of Alzheimer\u2019s disease: A systematic review","volume":"40","author":"Tay","year":"2024","journal-title":"Value Health Reg Issues"},{"key":"10.3233\/JAD-240730_ref3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240730_ref4","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JAD-240730_ref5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-161088","article-title":"Oxidative stress, synaptic dysfunction, and Alzheimer\u2019s disease","volume":"57","author":"Tonnies","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240730_ref6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/00004728-198308000-00003","article-title":"Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose","volume":"7","author":"Friedland","year":"1983","journal-title":"J Comput Assist Tomogr"},{"key":"10.3233\/JAD-240730_ref7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240730_ref8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/alz.12683","article-title":"The role of mitochondrial dysfunction in Alzheimer\u2019s disease pathogenesis","volume":"19","author":"Ashleigh","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240730_ref9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"10.3233\/JAD-240730_ref10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med Clin North Am"},{"key":"10.3233\/JAD-240730_ref11","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1073\/pnas.75.11.5737","article-title":"Identification of insulin in rat brain","volume":"75","author":"Havrankova","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240730_ref12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1749-6632.1996.tb34448.x","article-title":"Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor","volume":"777","author":"Hoyer","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-240730_ref13","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00125-016-3996-2","article-title":"Cerebral cortex: A target and source of insulin?","volume":"59","author":"Csajbok","year":"2016","journal-title":"Diabetologia"},{"key":"10.3233\/JAD-240730_ref14","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbadis.2015.05.004","article-title":"High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents","volume":"1852","author":"Petrov","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"10.3233\/JAD-240730_ref15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neurobiolaging.2005.09.001","article-title":"Neuronal insulin signal transduction mechanisms in diabetes phenotypes","volume":"26","author":"Reagan","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240730_ref16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.nlm.2011.08.005","article-title":"Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes","volume":"96","author":"McNay","year":"2011","journal-title":"Neurobiol Learn Mem"},{"key":"10.3233\/JAD-240730_ref17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nlm.2010.02.002","article-title":"Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance","volume":"93","author":"McNay","year":"2010","journal-title":"Neurobiol Learn Mem"},{"key":"10.3233\/JAD-240730_ref18","doi-asserted-by":"crossref","first-page":"136587","DOI":"10.1016\/j.neulet.2022.136587","article-title":"Cognitive impairments in type 1 diabetes mellitus model mice are associated with synaptic protein disorders","volume":"777","author":"Wang","year":"2022","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-240730_ref19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1212\/WNL.50.1.164","article-title":"Cerebrospinal fluid and plasma insulin levels in Alzheimer\u2019s disease: Relationship to severity of dementia and apolipoprotein E genotype","volume":"50","author":"Craft","year":"1998","journal-title":"Neurology"},{"key":"10.3233\/JAD-240730_ref20","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: The Rotterdam Study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology"},{"key":"10.3233\/JAD-240730_ref21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","article-title":"Risk of dementia in diabetes mellitus: A systematic review","volume":"5","author":"Biessels","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240730_ref22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1212\/WNL.0b013e31822f0435","article-title":"Glucose tolerance status and risk of dementia in the community: The Hisayama study","volume":"77","author":"Ohara","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-240730_ref23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2337\/diabetes.53.2.474","article-title":"Increased risk of type 2 diabetes in Alzheimer disease","volume":"53","author":"Janson","year":"2004","journal-title":"Diabetes"},{"key":"10.3233\/JAD-240730_ref24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.61.5.661","article-title":"Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function","volume":"61","author":"Arvanitakis","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-240730_ref25","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2337\/diabetes.51.4.1256","article-title":"Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study","volume":"51","author":"Peila","year":"2002","journal-title":"Diabetes"},{"key":"10.3233\/JAD-240730_ref26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1212\/01.WNL.0000140291.86406.D1","article-title":"Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study","volume":"63","author":"Xu","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-240730_ref27","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1212\/01.WNL.0000144278.79488.DD","article-title":"Diabetes mellitus in midlife and the risk of dementia three decades later","volume":"63","author":"Schnaider Beeri","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-240730_ref28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/01.wnl.0000310646.32212.3a","article-title":"Impaired insulin secretion increases the risk of Alzheimer disease","volume":"71","author":"Ronnemaa","year":"2008","journal-title":"Neurology"},{"key":"10.3233\/JAD-240730_ref29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1445-5994.2012.02758.x","article-title":"Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies","volume":"42","author":"Cheng","year":"2012","journal-title":"Intern Med J"},{"key":"10.3233\/JAD-240730_ref30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2015_9","article-title":"Incretins","volume":"233","author":"Wu","year":"2016","journal-title":"Handb Exp Pharmacol"},{"key":"10.3233\/JAD-240730_ref31","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: A physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.3233\/JAD-240730_ref32","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1016\/S0021-9258(18)68261-4","article-title":"Glucagon gene expression in vertebrate brain","volume":"263","author":"Drucker","year":"1988","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-240730_ref33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/pr.55.1.6","article-title":"International Union of Pharmacology. XXXV. The glucagon receptor family","volume":"55","author":"Mayo","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.3233\/JAD-240730_ref34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1210\/endo.133.1.8391428","article-title":"Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C","volume":"133","author":"Wheeler","year":"1993","journal-title":"Endocrinology"},{"key":"10.3233\/JAD-240730_ref35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/endo.140.3.6550","article-title":"Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells","volume":"140","author":"Montrose-Rafizadeh","year":"1999","journal-title":"Endocrinology"},{"key":"10.3233\/JAD-240730_ref36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0896-6273(03)00228-9","article-title":"Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons","volume":"38","author":"Man","year":"2003","journal-title":"Neuron"},{"key":"10.3233\/JAD-240730_ref37","doi-asserted-by":"crossref","first-page":"20976","DOI":"10.1073\/pnas.0810119105","article-title":"Protein kinase A inhibits a consolidated form of memory in Drosophila","volume":"105","author":"Horiuchi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240730_ref38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/0-387-30128-3_3","volume-title":"Brain Repair","author":"Faissner","year":"2006"},{"key":"10.3233\/JAD-240730_ref39","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240730_ref40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-0115(03)00125-3","article-title":"GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine","volume":"114","author":"Mortensen","year":"2003","journal-title":"Regul Pept"},{"key":"10.3233\/JAD-240730_ref41","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240730_ref42","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jnr.21349","article-title":"Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain","volume":"85","author":"Nyberg","year":"2007","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-240730_ref43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2023.2438","article-title":"As Ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss","volume":"329","author":"Suran","year":"2023","journal-title":"JAMA"},{"key":"10.3233\/JAD-240730_ref44","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240730_ref45","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240730_ref46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 Analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.3233\/JAD-240730_ref47","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.3233\/JAD-240730_ref48","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer\u2019s disease","volume":"19","author":"Li","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240730_ref49","first-page":"3540","article-title":"Exendin-4 protects Abeta(1-42) oligomer-induced PC12 cell apoptosis","volume":"8","author":"Qiu","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.3233\/JAD-240730_ref50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/00207454.2018.1543671","article-title":"The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity","volume":"129","author":"Khalilnezhad","year":"2019","journal-title":"Int J Neurosci"},{"key":"10.3233\/JAD-240730_ref51","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s11357-012-9464-0","article-title":"Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice","volume":"35","author":"Rachmany","year":"2013","journal-title":"Age (Dordr)"},{"key":"10.3233\/JAD-240730_ref52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/jpet.300.3.958","article-title":"A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells","volume":"300","author":"Perry","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-240730_ref53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neurobiolaging.2017.12.009","article-title":"Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice","volume":"64","author":"Bomba","year":"2018","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240730_ref54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jnr.22565","article-title":"Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain","volume":"89","author":"Hamilton","year":"2011","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-240730_ref55","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer\u2019s disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-240730_ref56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/dot.2009.45.2.1343904","article-title":"Liraglutide: A new treatment for type 2 diabetes","volume":"45","author":"Vilsboll","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.3233\/JAD-240730_ref57","doi-asserted-by":"crossref","first-page":"661","DOI":"10.17219\/acem\/121007","article-title":"The role of GLP-1\/GIP receptor agonists in Alzheimer\u2019s disease","volume":"29","author":"Yu","year":"2020","journal-title":"Adv Clin Exp Med"},{"key":"10.3233\/JAD-240730_ref58","doi-asserted-by":"crossref","first-page":"108688","DOI":"10.1016\/j.cbi.2019.06.001","article-title":"The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells","volume":"310","author":"Zheng","year":"2019","journal-title":"Chem Biol Interact"},{"key":"10.3233\/JAD-240730_ref59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease","volume":"245","author":"Batista","year":"2018","journal-title":"J Pathol"},{"key":"10.3233\/JAD-240730_ref60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.12469","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress","volume":"128","author":"Sharma","year":"2014","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-240730_ref61","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jalz.2011.09.137","article-title":"The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer\u2019s disease (AD) cases","volume":"7","author":"Talbot","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240730_ref62","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240730_ref63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease","volume":"76 Pt A","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-240730_ref64","doi-asserted-by":"crossref","first-page":"e58784","DOI":"10.1371\/journal.pone.0058784","article-title":"Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model","volume":"8","author":"Parthsarathy","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-240730_ref65","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3233\/JAD-143090","article-title":"The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer\u2019s disease","volume":"46","author":"Hansen","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240730_ref66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240730_ref67","doi-asserted-by":"crossref","first-page":"17490","DOI":"10.1038\/s41598-017-17718-y","article-title":"Blood-brain glucose transfer in Alzheimer\u2019s disease: Effect of GLP-1 analog treatment","volume":"7","author":"Gejl","year":"2017","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-240730_ref68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behav Brain Res"},{"issue":"Suppl 9","key":"10.3233\/JAD-240730_ref69","doi-asserted-by":"crossref","first-page":"e057848","DOI":"10.1002\/alz.057848","article-title":"Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease","volume":"17","author":"Edison","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"Suppl 21","key":"10.3233\/JAD-240730_ref70","doi-asserted-by":"crossref","first-page":"e080538","DOI":"10.1002\/alz.080538","article-title":"MRI changes following treatment of GLP-1 analogue, Liraglutide in Alzheimer\u2019s disease","volume":"19","author":"Edison","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240730_ref71","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","article-title":"Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer\u2019s disease","volume":"495","author":"Cai","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-240730_ref72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbr.2016.10.033","article-title":"Lixisenatide attenuates the detrimental effects of amyloid beta protein on spatial working memory and hippocampal neurons in rats","volume":"318","author":"Cai","year":"2017","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-240730_ref73","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","article-title":"Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats","volume":"277","author":"Cai","year":"2014","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-240730_ref74","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease","volume":"86","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-240730_ref75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"10.3233\/JAD-240730_ref76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","article-title":"Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3beta","volume":"511","author":"Zhou","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-240730_ref77","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240730_ref78","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jocn.2020.09.054","article-title":"Semaglutide-mediated protection against Abeta correlated with enhancement of autophagy and inhibition of apoptosis","volume":"81","author":"Chang","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.3233\/JAD-240730_ref79","doi-asserted-by":"crossref","first-page":"109716","DOI":"10.1016\/j.neuropharm.2023.109716","article-title":"Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway","volume":"240","author":"Wang","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-240730_ref80","doi-asserted-by":"crossref","first-page":"042909","DOI":"10.1002\/alz.042909","article-title":"Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetese","volume":"16","author":"Ballard","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240730_ref81","doi-asserted-by":"crossref","first-page":"e062415","DOI":"10.1002\/alz.062415","article-title":"Evoke and evoke+: Design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer\u2019s disease","volume":"18","author":"Atri","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240730_ref82","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.brainres.2012.07.029","article-title":"Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B\/16 mouse brain","volume":"1473","author":"McGovern","year":"2012","journal-title":"Brain Res"},{"key":"10.3233\/JAD-240730_ref83","doi-asserted-by":"crossref","first-page":"BSR20171284","DOI":"10.1042\/BSR20171284","article-title":"GLP-1 receptor regulates cell growth through regulating IDE expression level in Abeta1-42-treated PC12 cells","volume":"38","author":"Li","year":"2018","journal-title":"Biosci Rep"},{"key":"10.3233\/JAD-240730_ref84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bbr.2017.03.018","article-title":"GLP-1 analogue CJC-1131 prevents amyloid beta protein-induced impirments of spatial memory and synaptic plasticity in rats","volume":"326","author":"Zhang","year":"2017","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-240730_ref85","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt174","article-title":"Neuroprotective effects of D-Ala(2)GIP on Alzheimer\u2019s disease biomarkers in an APP\/PS1 mouse model","volume":"5","author":"Faivre","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240730_ref86","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JAD-121888","article-title":"D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer\u2019s disease mouse model","volume":"35","author":"Faivre","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240730_ref87","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuroscience.2012.10.045","article-title":"The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"228","author":"Duffy","year":"2013","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-240730_ref88","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.3233\/JAD-240730_ref89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbr.2017.03.032","article-title":"A novel dual GLP-1\/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model","volume":"327","author":"Shi","year":"2017","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-240730_ref90","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3233\/JAD-210256","article-title":"A GLP-1\/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in the APP\/PS1\/tau model of Alzheimer\u2019s disease","volume":"83","author":"Cai","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240730_ref91","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JAD-240730_ref92","doi-asserted-by":"crossref","first-page":"e01505","DOI":"10.1002\/brb3.1505","article-title":"The novel GLP-1\/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD","volume":"10","author":"Li","year":"2020","journal-title":"Brain Behav"},{"key":"10.3233\/JAD-240730_ref93","doi-asserted-by":"crossref","first-page":"107813","DOI":"10.1016\/j.neuropharm.2019.107813","article-title":"Neuroprotective and restorative properties of the GLP-1\/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer\u2019s disease","volume":"162","author":"Salles","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-240730_ref94","doi-asserted-by":"crossref","first-page":"104640","DOI":"10.1016\/j.yhbeh.2019.104640","article-title":"A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP\/PS1 transgenic mice","volume":"118","author":"Wang","year":"2020","journal-title":"Horm Behav"},{"key":"10.3233\/JAD-240730_ref95","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-180584","article-title":"The novel DA-CH3 dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-like pathology and cognitive decrements in the APPSWE\/PS1DeltaE9 mouse model","volume":"66","author":"Panagaki","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240730_ref96","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"10.3233\/JAD-240730_ref97","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.3233\/JAD-240730_ref98","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hipo.22837","article-title":"A novel GLP-1\/GIP\/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer\u2019s disease","volume":"28","author":"Li","year":"2018","journal-title":"Hippocampus"},{"key":"10.3233\/JAD-240730_ref99","doi-asserted-by":"crossref","first-page":"108042","DOI":"10.1016\/j.neuropharm.2020.108042","article-title":"A GLP-1\/GIP\/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca(2+) homeostasis in 3xTg-AD mice","volume":"170","author":"Li","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-240730_ref100","unstructured":"Choi IY , Lee JS , Kim JK , Park YJ , Jung SY , Kim YH , Kwon SC (2017) Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1\/Glucagon\/GIP triple-agonist (HM15211). American Diabetes Association\u2019s 77th Scientific Session."},{"key":"10.3233\/JAD-240730_ref101","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease","volume":"1678","author":"Tai","year":"2018","journal-title":"Brain Res"},{"key":"10.3233\/JAD-240730_ref102","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-240730_ref103","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease","volume":"202","author":"Kim","year":"2009","journal-title":"J Endocrinol"},{"key":"10.3233\/JAD-240730_ref104","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-240730_ref105","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1038\/s41598-018-28449-z","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson\u2019s disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-240730_ref106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"10.3233\/JAD-240730_ref107","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson\u2019s disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JAD-240730_ref108","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.2337\/db19-990-P","article-title":"Effect of HM15211, a novel long-acting GLP-1\/GIP\/glucagon triple agonist in the neurodegenerative disease models","volume":"68","author":"Kim","year":"2019","journal-title":"Diabetes"},{"key":"10.3233\/JAD-240730_ref109","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240730_ref110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240730_ref111","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-240730_ref112","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.3233\/JAD-240730_ref113","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-240730_ref114","doi-asserted-by":"crossref","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-240730_ref115","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:59:21Z","timestamp":1777370361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-240730"}},"subtitle":[],"editor":[{"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Jesus","family":"Avila","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Pappolla","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Aaron A.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":115,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240730","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}